Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Pharmacokinetics
Published in: Clinical Pharmacokinetics 11/2006

01-11-2006 | Review Article

Guidelines on Paediatric Dosing on the Basis of Developmental Physiology and Pharmacokinetic Considerations

Authors: Dr Imke H. Bartelink, Carin M. A. Rademaker, Alfred F. A. M. Schobben, John N. van den Anker

Published in: Clinical Pharmacokinetics | Issue 11/2006

Login to get access

Abstract

The approach to paediatric drug dosing needs to be based on the physiological characteristics of the child and the pharmacokinetic parameters of the drug. This review summarises the current knowledge on developmental changes in absorption, distribution, metabolism and excretion and combines this knowledge with in vivo and in vitro pharmacokinetic data that are currently available. In addition, dosage adjustments based on practical problems, such as child-friendly formulations and feeding regimens, disease state, genetic make-up and environmental influences are presented.
Modification of a dosage based on absorption, depends on the route of absorption, the physico chemical properties of the drug and the age of the child. For oral drug absorption, a distinction should be made between the very young and children over a few weeks old. In the latter case, it is likely that practical considerations, like appropriate formulations, have much greater relevance to oral drug absorption.
The volume of distribution (Vd) may be altered in children. Hydrophilic drugs with a high Vd in adults should be normalised to bodyweight in young children (age <2 years), whereas hydrophilic drugs with a low Vd in adults should be normalised to body surface area (BSA) in these children. For drugs that are metabolised by the liver, the effect of the Vd becomes apparent in children <2 months of age. In general, only the first dose should be based on the Vd subsequent doses should be determined by the clearance. Pharmacokinetic studies on renal and liver function clarify that a distinction should be made between maturation and growth of the organs. After the maturation process has finished, the main influences on the clearance of drugs are growth and changes in blood flow of the liver and kidney. Drugs that are primarily metabolised by the liver should be administered with extreme care until the age of 2 months. Modification of dosing should be based on response and on therapeutic drug monitoring. At the age of 2–6 months, a general guideline based on bodyweight may be used. After 6 months of age, BSA is a good marker as a basis for drug dosing. However, even at this age, drugs that are primarily metabolised by cytochrome P450 2D6 and uridine diphosphate glucuronosyltransferase should be normalised to bodyweight.
In the first 2 years of life, the renal excretion rate should be determined by markers of renal function, such as serum creatinine and p-aminohippuric acid clearance. A dosage guideline for drugs that are significantly excreted by the kidney should be based on the determination of renal function in first 2 years of life. After maturation, the dose should be normalised to BSA.
These guidelines are intended to be used in clinical practice and to form a basis for more research. The integration of these guidelines, and combining them with pharmacodynamic effects, should be considered and could form a basis for further study.
Literature
1.
Rodman JH. Pharmacokinetic variability in the adolescent: implications of body size and organ function for dosage regimen design. J Adolesc Health 1994; 15(8): 654–62PubMedCrossRef
2.
Crawford JD, Terry ME, Rourke GM. Simplification of drug dosage calculation by application of the surface area principle. Pediatrics 1950; 5(5): 783–90PubMed
3.
Meine Jansen CF, Toet MC, Rademaker CM, et al. Treatment of symptomatic congenital cytomegalovirus infection with valganciclovir. J Perinat Med 2005; 33(4): 364–6
4.
Yaffe SJ, Aranda JV. Neonatal and pediatric pharmacology therapeutic principles in practice. 3rd ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2004
5.
6.
Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med 2003; 349: 1157–67PubMedCrossRef
7.
8.
Ritschel WA, Kearns GL. Handbook of basis pharmacokinetics including clinical applications. 6th ed. Washington, DC: American Pharmaceutical Association, 2004: 227–240
9.
Rennie JM, Roberten NRC. Textbook of neonatology. 3rd ed. Edinburgh: Churchill Livingstone, 1999
10.
McLeod HL, Relling MV, Crom WR, et al. Disposition of antineoplastic agents in the very young child: pharmacokinetics in children. Br J Cancer Suppl 1992; 18: S23–9PubMed
11.
Strolin Benedetti M, Baltes EL. Drug metabolism and disposition in children. Fundam Clin Pharmacol 2003; 17: 281–99CrossRef
12.
Kearns GL. Impact of developmental pharmacology on pediatric study desing; overcoming the challenges. J Allergy Clin Immunol 2000; 106: S128–39PubMedCrossRef
13.
Hunseler C, Roth B, Pothmann R, et al. Intramuscular injections in children [in German]. Schmerz 2005 Apr; 19(2): 140–3PubMedCrossRef
14.
Jatzen JP, Diehl P. Rectal administration of drugs: fundamentals and applications in anesthesia [in German]. Anaesthesist 1991; 40(5): 251–61
15.
American Academy of Pediatrics Committee on Drugs. Alternative routes of drug administration: advantages and disadvantages. Pediatrics 1997; 100: 143–52CrossRef
16.
Anderson BJ, van Lingen RA, Hansen TG, et al. Acetaminophen developmental pharmacokinetics in premature neonates and infants: a pooled population analysis. Anesthesiology 2002; 96(6): 1336–45PubMedCrossRef
17.
Kearns GL, Robinson PK, Wilson JT, et al. Pharmacokinetics and drug disposition cisapride disposition in neonates and infants: in vivo reflection of cytochrome P450 3A4 ontogeny. Clin Pharmacol Ther 2003; 4: 312–25CrossRef
18.
Kearns GL, Bradley JS, Jacobs RF, et al. Single dose pharmacokinetics of pleconaril in neonates. Pediatr Infect Dis J 2000; 19(9): 833–9PubMedCrossRef
19.
de Wildt SN, Kearns GL, Hop WC, et al. Pharmacokinetics and metabolism of oral midazolam in preterm infants. Br J Clin Pharmacol 2002 Apr; 53(4): 390–2PubMedCrossRef
20.
Boucher FD, Modlin JF, Weiler S, et al. Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus. J Pediatr 1993; 122: 1137–44
21.
Capparelli EV, Mirochnick M, Dankner WM, et al. Pharmacokinetics and tolerance of zidovudine in preterm infants. J Pediatr 2003; 142: 47–52PubMedCrossRef
22.
Albani M, Wernicke I. Oral phenytoin in infancy: dose requirement, absorption, and elimination. Pediatr Pharmacol (New York) 1983; 3(3–4): 229–36
23.
de Repentigny L, Ratelle J, Leclerc JM, et al. Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. Antimicrob Agents Chemother 1998; 42(2): 404–8PubMed
24.
Abdel-Rahman SM, Johnson FK, Connor JD, et al. Developmental pharmacokinetics and pharmacodynamics of nizatidine. J Pediatr Gastroenterol Nutr 2004; 38(4): 442–51PubMedCrossRef
25.
Kokki H, Karvinen M, Suhonen P. Pharmacokinetics of intravenous and rectal ketoprofen in young children. Clin Pharmacokinet 2003; 42(4): 373–9PubMedCrossRef
26.
Ishizaki T, Sasaki T, Suganuma T. Pharmacokinetics of ketoprofen following single oral, intramuscular and rectal doses and after repeated oral administration. Eur J Clin Pharmacol 1980; 18(5): 407–14PubMedCrossRef
27.
van Lingen RA, Deinum JT, Quak JME, et al. Pharmacokinetics and metabolism of rectally administered paracetamol in preterm neonates. Arch Dis Child Fetal Neonatal Ed 1999; 80: F59–63PubMedCrossRef
28.
Zwaveling J, Bubbers S, van Meurs AH, et al. Pharmacokinetics of rectal tramadol in postoperative paediatric patients. Br J Anaesth 2004; 93(2): 224–7PubMedCrossRef
29.
Rudolph AM, Kamei RK, Overby K J. Rudolph’s fundamentals of pediatrics. 2nd ed. Stanford: Appleton & Lange, 1998: 400
30.
Ginsberg G, Hattis D, Miller M, et al. Pediatrie pharmacokinetic data: implications for environmental risk assessment for children. Pediatrics 2004; 113(4): 973–83PubMed
31.
Kimura T, Sunakawa K, Matsuura N, et al. Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates. Antimicrob Agents Chemother 2004; 48(4): 1159–67PubMedCrossRef
32.
Bartels H. Drug therapy in childhood: what has been done and what has to be done? Pediatr Pharmacol (New York) 1983; 3: 131–43
33.
Kearns GL, Jungbluthy GL, Abdel-Rahman SM, et al. Impact of ontogeny on linezolid disposition in neonates and infants. Clin Pharmacol Ther 2003; 74(5): 413–22PubMedCrossRef
34.
Hayani KC, Hatzopoulos FK, Frank AL, et al. Pharmacokinetics of once-daily dosing of gentamicin in neonates. J Pediatr 1997; 131: 76–80PubMedCrossRef
35.
Watterberg KL, Kelly HW, Angelus P, et al. The need for a loading dose of gentamicin in neonates. Ther Drug Monit 1989; 11(1): 16–20PubMedCrossRef
36.
Allegaert K, Anderson BJ, Verbesselt R, et al. Tramadol disposition in the very young: an attempt to assess in vivo cytochrome P-450 activity. Br J Anaesth 2005; 95(2): 231–9PubMedCrossRef
37.
Anderson GD. Children versus adults: pharmacokinetic and adverse-effect differences. Epilepsia 2002; 43: 53–9PubMedCrossRef
38.
Capparelli EV, Lane JR, Romanowski GL, et al. The influences of renal function and maturation on vancomycin elimination in newborns and infants. J Clin Pharmacol 2001; 41: 927–34PubMedCrossRef
39.
Alcorn J, McNamara PJ. Ontogeny of hepatic and renal systemic clearance pathways in infants part 1. Clin Pharmacokinet 2002; 41(12): 959–98PubMedCrossRef
40.
Rating D, Jager-Roman E, Nau H, et al. Enzyme induction in neonates after fetal exposure to antiepileptic drugs. Pediatr Pharmacol (New York) 1983; 3(3–4): 209–18
41.
Morselli PL. Antiepileptic drugs. Milan: 1976: 1–45
42.
Pineiro-Carrero VM, Pineiro EO. Liver. Pediatrics 2004; 113 (4 Suppl.): 1097–106PubMed
43.
Wildt SN, Kearns GL, Leeder JS, et al. Glucuronidation in humans: pharmacogenitic and developmental aspects. Clin Pharmacokinet 1999; 36(6): 439–43PubMedCrossRef
44.
Wildt SN, Kearns GL, Leeder JS, et al. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet 1999; 37(6): 485–505PubMedCrossRef
45.
Bouwmeester NJ, Anderson BJ, Tibboel D, et al. Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. Br J Anaesth 2004 Feb; 92(2): 208–17PubMedCrossRef
46.
Murry DJ, Crom WR, Reddick WE, et al. Liver volume as a determinant of drug clearance in children and adolescents. Drug Metab Dispos 1995; 23(10): 1110–6PubMed
47.
Kanamori M, Takahaski H, Echizen H. Developmental changes in the liver weight- and body weight-normalized clearance of theophylline, phenytoine and cyclosporine in children. Int J Clin Pharmacol Ther 2002; 40(11): 485–92PubMed
48.
Blanco JG, Harrison PL, Evans WE, et al. human cytochrome P450 maximal activities in pediatric versus adult liver. Drug Metab Dispos 2000; 28(4): 379–82PubMed
49.
Björkman S. Prediction of cytochrome P450-mediated hepatic drug clearance in neonates, infants and children: how accurate are available scaling methods? Clin Pharmacokinet 2006; 45(11): 1–11PubMedCrossRef
50.
Ginsberg G, Hattis D, Miller M, et al. Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. Toxicol Sci 2002; 66: 185–200PubMedCrossRef
51.
Alcorn J, McNamara PJ. Ontogeny of hepatic and renal systemic clearance pathways in infants part 2. Clin Pharmacokinet 2002; 41(13): 1077–94PubMedCrossRef
52.
Murat I, Billard V, Vernois J, et al. Pharmacokinetics of propofol after a single dose in children aged 1–3 years with minor burns: comparison of three data analysis approaches. Anesthesiology 1996 Mar; 84(3): 526–32PubMedCrossRef
53.
Kataria BK, Ved SA, Nicodemus HF, et al. The pharmacokinetics of propofol in children using three different data analysis approaches. Anesthesiology 1994 Jan; 80(1): 104–22PubMedCrossRef
54.
Valtonen M, Lisalo E, Kanto J, et al. Propofol as an induction agent in children: pain on injection and pharmacokinetics. Acta Anaesthesiol Scand 1989; 33: 152–5PubMedCrossRef
55.
Knibbe CAJ, Zuideveld KP, Aarts LPHJ, et al. Allometric relationships between the pharmacokinetics of propofol in rats, children and adults. Br J Clin Pharmacol 2005; 59(6): 705–11PubMedCrossRef
56.
Evans WE, Relling MV, de Graaf S, et al. Hepatic drug clearance in children: studies with indocyanine green as a model substrate. J Pharmaceut Sci 1989 Jun; 78(6): 452–6CrossRef
57.
Cooney GF, Habucky K, Hoppu K. Cyclosporin pharmacokinetics in paediatric transplant recipients. Clin Pharmacokinet 1997; 32(6): 481–95PubMedCrossRef
58.
Kearns GL, Andersson T, James LP, et al. Omeprazole disposition in infants and children; role of age and CYP2C19 genotype. J Clin Pharmacol 2003 Aug; 43(8): 840–8PubMedCrossRef
59.
Crom WR, Relling MV, Christensen ML, et al. Age-related differences in hepatic drug clearance in children: studies with lorazepam and antipyrine. Clin Pharmacol Ther 1991; 50(2): 132–40PubMedCrossRef
60.
Hunt A, Joel S, Dick G, et al. Population pharmacokinetics of oral morphine and its glucuronides in children receiving morphine as immediate-release liquid or sustained-release tablets for cancer pain. J Pediatr 1999 Jul; 135(1): 47–55PubMedCrossRef
61.
Bakshi SS, Britto P, Capparelli E, et al. Evaluation of pharmacokinetics, safety, tolerance, and activity of combination of zalcitabine and zidovudine in stable, zidovudine-treated pediatric patients with human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 190 Team. J Infect Dis 1997 May; 175(5): 1039–50PubMedCrossRef
62.
Payne KA, Roelofse JA, Shipton EA. Pharmacokinetics of oral tramadol drops for postoperative pain relief in children aged 4 to 7 years: a pilot study. Anesth Prog 2002; 49(4): 109–12PubMed
63.
Murthy BVS, Pandya KS, Booker PD, et al. Pharmacokinetics of tramadol in children after i.V. or caudal epidural administration. Br J Anaesth 2000; 84(3): 346–9PubMedCrossRef
64.
Van Der Marel CD, Anderson BJ, Van Lingen RA, et al. Paracetamol and metabolite pharmacokinetics in infants. Eur J Clin Pharmacol 2003; 59: 243–51PubMedCrossRef
65.
Yared A, Ichikawa I. Glomerular circulation and function in pediatric nephrology. 3rd ed. Baltimore: Williams and Wilkins, 1994: 39–55
66.
Brande van den JL, Gelderen van HH, Monnens LAH. Pediatrics [in Dutch]. Utrecht: Bunge, 1990
67.
Bird NJ, Henderson BL, Lui D, et al. Indexing glomerular filtration rate to suit children. J Nucl Med 2003; 44: 1037–4PubMed
68.
Sawyer M, Ratain MJ. Body surface area as a determinant of pharmacokinetics and drug dosing. InvestNew Drugs 2001; 19(2): 171–7PubMedCrossRef
69.
Hayton WL. Maturation and growth of renal faction: dosing renally cleared drugs in children. AAPS PharmSci 2002; 2(3): e3
70.
Peters AM, Henderson BL, Lui D. Indexed glomerular filtration rate as a function of age and body size. Clin Sci 2000; 98: 439–44PubMedCrossRef
71.
Siegel SR, Oh W. Renal function as a marker of human fetal maturation. Acta Paediatr Scand 1976; 65: 481–5PubMedCrossRef
72.
Gallini F, Maggio L, Romagnoli C, et al. Progression of renal function in preterm neonates with gestational age ≤32 weeks. Pediatr Nephrol 2000; 14: 119–24CrossRef
73.
Rennie JM, Roberten NRC. Textbook of neonatology. 3rd ed. Edinburgh: Churchill Livingstone, 1999: 417–433
74.
Filler G, Lepage N. Should the Schwartz formula for estimation of GFR be replaced by cystatin C formula? Pediatr Nephrol 2003 Oct; 18(10): 981–5PubMedCrossRef
75.
Brion LP, Fleischman AR, Schwartz GJ. Gentamicin interval in newborn infants as determined by renal function and postconceptional age. Pediatr Nephrol 1991; 5: 675–8PubMedCrossRef
76.
Schwartz GJ, Haycock GB, Edelmann CM, et al. Simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976; 58: 259–63PubMed
77.
Hogg RJ, Furth S, Lemley KV, et al. National Kidney Foundation’s kidney disease outcomes quality initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. Pediatrics 2003; 111(6): 1416–21PubMedCrossRef
78.
Counahan R, Chantier C, Ghazali S, et al. Estimation of glomerular filtration rate from plasma creatinine concentration in children. Arch Dis Child 1976; 51: 875–8PubMedCrossRef
79.
Morris MC, Allanby CW, Tolesland P, et al. Evaluation of a height/plasma creatinine formula in the measurement of glomerular filtration rate. Arch Dis Child 1982; 57: 611–5PubMedCrossRef
80.
Leger F, Bouissou F, Coulais Y, et al. Estimation of glomerular filtration rate in children. Pediatr Nephrol 2002; 17: 903–7PubMedCrossRef
81.
Hellerstein S, Alon U, Warady BA. Creatinine for estimation of glomerular filtration rate. Pediatr Nephrol 1992; 6(6): 507–11PubMedCrossRef
82.
Pierrat A, Gravier E, Saunders C, et al. Predicting GFR in children and adults: a comparison of the Cockcroft-Gault, Schwartz and Modification of Diet in Renal Disease formulas. Kidney Int 2003; 64: 1425–36PubMedCrossRef
83.
Saul JP, Schaffer MS, Karpawich PP, et al. Single-dose pharmacokinetics of sotalol in a pediatric population with supraventricular and/or ventricular tachyarrhythmia. J Clin Pharmacol 2001; 41(1): 35–43PubMedCrossRef
84.
Rossum LK, Mathot RAA, Cransberg K, et al. Estimation of the glomerular filtration rate in children: which algorithm should be used? Pediatr Nephrol 2005; 20: 1769–75PubMedCrossRef
85.
van den Anker JN, de Groot R, Broerse HM, et al. Assessment of glomerular filtration rate in preterm infants by serum creatinine: comparison with inulin clearance. Pediatrics 1995 Dec; 96(6): 1156–8PubMed
86.
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41PubMedCrossRef
87.
Reed MD, Kliegman RM, Yamashita TS, et al. Clinical pharmacology of imipenem and cilastatin in premature infants during the first week of life. Antimicrob Agents Chemother 1990; 34(6): 1172–7PubMedCrossRef
88.
Jacobs RF, Kearns GL, Brown AL, et al. Renal clearance of imipenem in children. Eur J Clin Microbiol 1984; 3(5): 471–4PubMedCrossRef
89.
Soyka LF. Pediatric clinical pharmacology of digoxin. Pediatr Clin North Am 1981 Feb; 28(1): 203–16PubMed
90.
De Hoog M, Mouton JW, van den Anker JN. New dosing strategies for antibacterial agents in the neonate. Semin Fetal Neonatal Med 2005; 10: 185–94PubMedCrossRef
91.
Thomson AH, Kerr S, Wright S. Population pharmacokinetics of caffeine in neonates and young infants. Ther Drug Monit 1996 Jun; 18(3): 245–53PubMedCrossRef
92.
Paul D, Standifer KM, Inturrisi CE, et al. Pharmacological characterization of morphine-6 beta-glucuronide, a very potent morphine metabolite. Pharmacol Exp Ther 1989; 251(2): 447–83
93.
Fanaroff AA, Martin RJ, editors. Neonatal-perinatal medicine. 7th ed. New York: Elsevier, 2001
94.
Rigby-Jones AEB, Nolan JA, Priston MJ, et al. Pharmacokinetics of propofol infusions in critically ill neonates, infants, and children in an intensive care unit. Anesthesiology 2002; 97(6): 1393–400PubMedCrossRef
95.
Rodman JH, Relling MV, Stewart CF, et al. Clinical pharmacokinetics and pharmacodynamics of anticancer drugs in children. Semin Oncol 1993; 20(1): 18–29PubMed
96.
van den Anker JN, Hop WC, de Groot R, et al. Effects of prenatal exposure to betamethasone and indomethacin on the glomerular filtration rate in the preterm infant. Pediatr Res 1994 Nov; 36(5): 578–81PubMedCrossRef
97.
Zwaveling J, Bredius RGM, Cremers SCLM, et al. Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity. Bone Marrow Transplant 2005 Jan; 35(1): 17–23PubMedCrossRef
98.
Kleinknecht D, Ganeval D, Droz D. Acute renal failure after high doses of gentamicin and cephalothin. Lancet 1973; I: 1129CrossRef
99.
Soldin OP, Soldin SJ. Review: therapeutic drug monitoring in pediatrics. Ther Drug Monit 2002; 24: 1–8PubMedCrossRef
100.
Johnson TN. Modelling approaches to dose estimation in children. Br J Clin Pharmacol 2005; 59(6): 663–9PubMedCrossRef
101.
Baber NS. Tripartite meeting. Paediatric regulatory guidelines: do they help in optimizing dose selection for children? Br J Clin Pharmacol 2005; 69(6): 660–2CrossRef
102.
Laer S, Elshoff JP, Meibohm B, et al. Development of a safe and effective pediatric dosing regimen for sotalol based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia. J Am Coll Cardiol 2005; 46(7): 1322–30PubMedCrossRef
103.
Bjorkman S. Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. Br J Clin Pharmacol 2004; 59(6): 691–704CrossRef
104.
Ginsberg G, Hattis D, Russ A, et al. Physiologically based pharmacokinetic (PBPK) modeling of caffeine and theophylline in neonated and adults: implications for assessing children/s risks from environmental agents. J Toxicol Environ Health A 2004; 67: 297–329PubMedCrossRef
Metadata
Title
Guidelines on Paediatric Dosing on the Basis of Developmental Physiology and Pharmacokinetic Considerations
Authors
Dr Imke H. Bartelink
Carin M. A. Rademaker
Alfred F. A. M. Schobben
John N. van den Anker
Publication date
01-11-2006
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 11/2006
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.2165/00003088-200645110-00003

Other articles of this Issue 11/2006

Clinical Pharmacokinetics 11/2006 Go to the issue

Original Research Article

Aliskiren Exhibits Similar Pharmacokinetics in Healthy Volunteers and Patients with Type 2 Diabetes Mellitus

Leading Article

Pharmacokinetic Variability of Newer Antiepileptic Drugs

Original Research Article

Sirolimus Population Pharmacokinetic/Pharmacogenetic Analysis and Bayesian Modelling in Kidney Transplant Recipients

Current Opinion

Fatal Respiratory Depression after Multiple Intravenous Morphine Injections

Original Research Article

Population Pharmacokinetics of Itraconazole and its Active Metabolite Hydroxy-Itraconazole in Paediatric Cystic Fibrosis and Bone Marrow Transplant Patients

Original Research Article

Pharmacokinetics and Dosing Recommendations of Tenofovir Disoproxil Fumarate in Hepatic or Renal Impairment